Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
about
Biomarkers of treatment response in multiple sclerosisEfficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureClinical trials in progressive multiple sclerosis: lessons learned and future perspectivesFingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosisThe clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood.A multi-biomarker follow-up study of patients with multiple sclerosis.N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis--commentary.Science is 1% inspiration and 99% biomarkers.Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.Should we start evaluating intrathecal IgM production clinically?T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosisNeurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis studyThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO
P2860
Q28305094-42DE5C4C-0023-49B6-8829-CD9DA434F986Q33573208-B6D533D0-FF99-4A93-B4FB-016D1F107E8CQ34570124-F084CEE1-EFE9-46A5-ACDC-E9E40D79DF4AQ35078327-4AAF1761-4059-413A-A326-BC03F311BB75Q35182733-B308C06B-B19C-4295-9C97-507E590ADE41Q35537489-7E915FDD-8A1A-47D5-BE4C-A0982871C568Q38910574-2210FD35-C430-4BEC-82C0-8732C3021BA5Q38960854-0A254A43-408E-4B60-9CB8-99EDEFD6E7CBQ39044367-0FA2CDD0-90A3-415D-A5E2-81308ECBE3F5Q41182006-95044D18-7C09-4C03-A30E-367BC96E9FF0Q42683530-00C48CCA-3BF9-4A91-B5AF-F14295A7C3BEQ47579410-A463546D-247B-4C84-B5BE-F3932AA41758Q47638443-612BCD6A-844E-484D-BACA-1904FCB72297Q48359316-B145217D-9B9F-4195-9133-FE4DA662A92BQ50984144-04A53DFC-472F-47A7-A411-EB7A30A29F0BQ53212006-E1AB5786-572A-4A8C-A910-4A95A0F9C4E1Q53653405-0C0D3562-0FE5-468B-A0E9-29F03D2AF152Q56873447-AAA3E084-03C5-46FC-B5C5-DB8B0122F4C0Q57161829-DC18669C-642F-4F02-95A2-72A1A5AC7D3AQ57601807-13EFC0A4-31FB-4B54-B222-4F5F969B1FB0
P2860
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Neurofilament light and heavy ...... markers in multiple sclerosis.
@en
Neurofilament light and heavy ...... markers in multiple sclerosis.
@nl
type
label
Neurofilament light and heavy ...... markers in multiple sclerosis.
@en
Neurofilament light and heavy ...... markers in multiple sclerosis.
@nl
prefLabel
Neurofilament light and heavy ...... markers in multiple sclerosis.
@en
Neurofilament light and heavy ...... markers in multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Neurofilament light and heavy ...... markers in multiple sclerosis.
@en
P2093
K Plattner
M Axelsson
O Yaldizli
P2860
P356
10.1111/ANE.12151
P407
P577
2013-06-13T00:00:00Z